1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Acuitas Therapeutics Names Miranda Lam as

01/13/2022 | 09:50am EDT

Chief Legal Officer & Sr. Director, Business Development Vancouver, B.C. - Miranda Lam has joined Acuitas Therapeutics as Chief Legal Officer & Sr. Director, Business Development, Acuitas President and CEO, Dr. Thomas Madden, announced recently. Ms. Lam comes to the newly created position on the Acuitas executive team from the Canadian national law firm McCarthy Tetrault LLP, where she was an equity partner.

Ms. Lam received her Bachelor of Laws from the University of British Columbia. She has been recognized as a leading lawyer in a range of respected independent publications such as Chambers Canada, Best Lawyers in Canada and Benchmark Canada: The Definitive Guide to Canada's Leading Litigation Firms and Attorneys. She was named in Vancouver Magazine's Power 50 List of the City's Most Influential People (2018) and was identified as a Leading Lawyer Under 40 by Lexpert (2017), 'Best 40 Under 40' Lawyer by the National Asian Pacific American Bar Association (2015), and was the recipient of the Association of Women in Finance's PEAK Women in Finance 'Rising Star' Award (2014). She was also named as one of Business in Vancouver's 'Forty Under 40' (2013). Ms. Lam is a recognized speaker and advocate for diversity and inclusion and sits on the board of directors of the BC Cancer Foundation.

'Acuitas has increased its global profile over the past two years as our lipid nanoparticle delivery system plays a key role in mRNA vaccines, including the BioNTech/Pfizer COVID-19 vaccine COMIRNATY. Miranda's extensive legal and business experience, exceptional relationship- building skills, and her collaborative, team-focused approach will be invaluable to our organization,' said Dr Madden. He added, 'Everyone on the team is looking forward to working with Miranda as we continue to support our partners to bring new therapeutics to patients.'

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.



Paul Holman

AHA Creative Strategies Inc.

Email: paul@ahacreative.com

T: 604-846-8461

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about BIONTECH SE
05/17Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
05/17UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating
05/17Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
05/17Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
05/17PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech..
05/16European ADRs Move Higher in Monday Trading
05/16WALL STREET STOCK EXCHANGE : China added to the list of investors' fears
05/16Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European C..
05/15Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Sales 2022 16 795 M 17 691 M 17 691 M
Net income 2022 8 929 M 9 404 M 9 404 M
Net cash 2022 16 669 M 17 557 M 17 557 M
P/E ratio 2022 4,40x
Yield 2022 -
Capitalization 36 869 M 38 834 M 38 834 M
EV / Sales 2022 1,20x
EV / Sales 2023 0,98x
Nbr of Employees 3 082
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 151,71 €
Average target price 225,86 €
Spread / Average Target 48,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-38.01%38 834
GILEAD SCIENCES, INC.-12.99%79 248
WUXI APPTEC CO., LTD.-16.20%42 682
GENMAB A/S-20.15%19 472